NASH clinical trial presentation and continued revenue growth
09 nov. 2018 06h00 HE
|
Immuron Limited
Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San FranciscoTravelan® on display at HealthEdAustralian Travelan® sales continue to...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05 sept. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
25 juil. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17.US Travelan® sales continue to exceed...
Immuron Announces it has Received a European Patent Grant for NASH treatment
24 juil. 2018 06h30 HE
|
Immuron Limited
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally...
US Department of Defense Research Collaboration Moves Forward
24 juil. 2018 06h28 HE
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
07 mai 2018 21h43 HE
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
13 mars 2018 02h15 HE
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Commences US Non-Deal Institutional Investor Roadshow
12 mars 2018 08h17 HE
|
Immuron Limited
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Limited Issues Correction to Misleading Halt Announcement Headline
07 mars 2018 17h06 HE
|
Immuron Limited
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. ...
Travelan® Revenue Grows Significantly in US and Australia
16 févr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: Immuron’s flagship product Travelan® reports revenue in excess of AUS$914K for first 6mths of FY2018 Travelan® US experienced a 250% increase in sales year over year reaching...